Glenmede Trust’s Oramed Pharmaceuticals ORMP Stock Holding History

Glenmede Trust’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,044	Closed	-$23K	–	1924
2020 Q3	$23K	Sell	9,044 -956	-10%	-$3.33K	﹤0.01%	1576
2020 Q2	$35K	Hold	10,000	–	–	﹤0.01%	1409
2020 Q1	$51K	Hold	10,000	–	–	﹤0.01%	1689
2019 Q4	$51K	Sell	10,000 -10,000	-50%	-$37.5K	﹤0.01%	1689
2019 Q3	$63	Hold	20,000	–	–	﹤0.01%	1557
2019 Q2	$71	Hold	20,000	–	–	﹤0.01%	1534
2019 Q1	$72	Hold	20,000	–	–	﹤0.01%	1522
2018 Q4	$60	Hold	20,000	–	–	﹤0.01%	1521
2018 Q3	$97K	Hold	20,000	–	–	﹤0.01%	1297
2018 Q2	$149K	Hold	20,000	–	–	﹤0.01%	1147
2018 Q1	$180K	Hold	20,000	–	–	﹤0.01%	1211
2017 Q4	$180K	Hold	20,000	–	–	﹤0.01%	1211
2017 Q3	$198K	Sell	20,000 -10,000	-33%	-$86.2K	﹤0.01%	1228
2017 Q2	$184K	Hold	30,000	–	–	﹤0.01%	1225
2017 Q1	$184K	Buy	+30,000	New	+$187K	﹤0.01%	1225
2014 Q1	–	Sell	-1,000	Closed	-$15K	–	2372
2013 Q4	$15K	Buy	+1,000	New	+$7.7K	﹤0.01%	1895

Other funds holding ORMP

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Glenmede Trust's ORMP Position: Q4 2020 in Review

Glenmede Trust sold out of Oramed Pharmaceuticals (ORMP) in Q4 2020, closing a stake of 9,044 shares — an estimated $23K sold.

Glenmede Trust first reported a position in ORMP in Q4 2013 and held it in 16 quarters. The position peaked at $198K in Q3 2017. 39 funds tracked by Wall St. Rank hold ORMP as of Q4 2020.

Glenmede Trust reported no remaining Oramed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 9,044 Oramed Pharmaceuticals shares in Q4 2020, an estimated $23K.
Glenmede Trust first reported a position in Oramed Pharmaceuticals in Q4 2013 and held it in 16 quarters.
Glenmede Trust's Oramed Pharmaceuticals position peaked at $198K in Q3 2017.
39 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.